Cohort 2 BioVenture Builder: Selection process started
Many early‑stage biotech founders get stuck between preclinical validation and investor readiness. That’s why the BOM is launching a new cohort of the BioVenture Builder this September: a sector‑specific venture development program designed to accelerate your biotech toward investment readiness, especially in today’s challenging fundraising climate.
After a strong first cohort (with startups in oncology, women’s health, and cardiovascular innovation), we are now selecting five new startups for Cohort 2.
What you’ll gain
Throughout the program, you will work with our experts on:
- Unmet medical need & patient stratification/identification
- Preclinical PoC development
- Clinical & regulatory strategy
- IP & exit strategy
- Leadership & team competencies
- Roadmapping, budgeting & fundraising
Participation is free and open to startups across the Netherlands. A voucher provides access to expertise in preclinical/clinical development, regulatory strategy, IP, and team development - allowing you to scale across all critical dimensions simultaneously.
Who they're looking for
- Innovative biotech/pharma startups addressing a clinically relevant problem
- Strong IP potential
- Committed founders
- Incorporated
Selection process
- Short introductory call (15 minutes)
- Review of your non‑confidential deck
- Q&A meeting
- Selection + NDA
- Program start:
- Onboarding: 7 September 2026
- Explorer phase: 8 November 2026
Ready to accelerate?
Schedule a short introductory call with Britta Driessen via the booking link. There are only have five spots available!
